Publication
Isocyanate-Modified Melatplatin(IV) Enhances Antitumor Efficacy via TCF4/COL6A3-Mediated Extracellular Matrix Remodeling and cGAS-STING Pathway Activation in Bladder Cancer.
Linhui Wang, Xiaomeng Liu, Tao Zhu, Zirun Su, Ruiping Liu, Zhe Li, Kaixuan Du, Kaipeng Jia, Chong Fu, Yuda Lin, Zihan Xue, Zhe Zhang, Chong Shen, Yunkai Qie, Zhouliang Wu, Zhiheng Liu, Kangkang Liu, Jingyuan Xu, Hailong Hu
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Cisplatin (CDDP) chemosensitivity and severe toxicity severely limit its clinical application in muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). To address these unmet clinical needs, we synthesized a series of melatonin-conjugated platinum(IV) prodrugs…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Bladder Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available